Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,904 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: AstraZeneca Clear all

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Breast Cancer
Interventions: Sapacitabine, Olaparib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Healthy
Interventions: AZD2624; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 30
States / cities: Bakersfield, California • Beverly Hills, California • Burbank, California + 25 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, sitagliptin, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Warfarin, Digoxin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Head and Neck Cancer
Interventions: Not listed
Lead sponsor: Foundation for the National Institutes of Health; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
Interventions: exenatide, Other antidiabetic therapies, No diabetes therapy; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 363,766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Advanced Ovarian Cancer
Interventions: None (Observational Study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 7
States / cities: Tampa, Florida • Shreveport, Louisiana • Annapolis, Maryland + 4 more

Conditions: Type 2 Diabetes
Interventions: placebo, exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 40
States / cities: Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, metformin, sitagliptin, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 18
States / cities: Buena Park, California • Los Angeles, California • Valencia, California + 15 more

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Rialto, California • Miami, Florida • Orlando, Florida + 2 more

Conditions: Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: Ceralasertib, Olaparib, Durvalumab; Drug
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 3
States / cities: Duarte, California • San Francisco, California • Chicago, Illinois

Conditions: Diabetes Mellitus, Type 2
Interventions: Saxagliptin, Dapagliflozin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Heart Failure, Heart Failure
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: The TIMI Study Group; Other
Eligibility: 18 Years and older
Enrollment: 2,401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19
Interventions: AZD7442, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 50
States / cities: Guntersville, Alabama • Tempe, Arizona • Little Rock, Arkansas + 42 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 80
States / cities: Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab (MEDI 4736), Radiotherapy; Drug · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • New York, New York

Conditions: Renal Impairment
Interventions: Opemalirsen (AZD2373); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Prostate Cancer
Interventions: Docetaxel, ZD4054, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 25
States / cities: Greenbrae, California • San Diego, California • Norwich, Connecticut + 22 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 17
States / cities: Los Angeles, California • Rolling Hills Estates, California • Clearwater, Florida + 14 more

Conditions: Lung Cancer, Carcinoma, Non-Small Cell Lung
Interventions: consolidative hypofractionated radiation therapy (hfRT), Durvalumab 50 MG/ML; Radiation · Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Breast Cancer
Interventions: Germline BRCA Test (blood), FoundationOne Dx Genomic Profile (archival Tumour Specimen), Follow-up; Genetic · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 873 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Santa Barbara, California • Denver, Colorado • Hialeah, Florida + 10 more

Conditions: Healthy Participants
Interventions: AZD0780, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Brooklyn, Maryland

Search by objective public record fields.

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels